Generium launches the first biosimilar drug to eculizumab, known as Elizaria. What is a biosimilar? What might this biosimilar mean for aHUS patients, and the physicians who treat them? The aHUS Alliance looks at the science behind biosimilars, as well as issues such as drug cost and access for those affected by the rare disease atypical HUS.
As it is obligated to do, on 14 May 2019 Alexion will be holding its shareholders meeting to report on how…
Along with the question about withdrawal from Complement inhibitor treatment , aHUS patients consider that research into the state of aHUS…
The aHUS Alliance presents issues and information from varied perspectives within the atypical HUS arena. Amplifying the patient voice in over 30 countries, we present this series of original content on topics related to the rare disease atypical HUS with articles focused on key interests of patients, caregivers, physicians, researchers and other stakeholders,
Just over two years ago the alliance reported on an event in India where key aHUS clinicians met to discuss and…
The aHUS alliance global action is an incorporated charitable organisation registered with the Charities Commission in the UK. It has to…
Ravulizumab has not featured in an aHUS alliance news item heading before. Ravulizumab has been watched by the alliance from its…
Nashville singer & songwriter Cameron James talks with the aHUS Alliance about finding a new rhythm for her life after her daughter and husband both were diagnosed with the rare disease atypical hemolytic uremic syndrome (atypical HUS or aHUS).
Most of the aHUS community are aware that aHUS is the result of predisposing genetic factors ,some known some not yet…